A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.
Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).
The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.
A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.
The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.
People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.
Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.
Increased BMI and insulin resistance are important predictors of diabetic ketoacidosis risk among people with type 1 diabetes using SGLT2 inhibitors, say the authors of a meta-analysis and meta-regression.
The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.
A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.